Real-world utilities and health-related quality-of-life data in hemophilia patients in France and the United Kingdom

References

• Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The hemophilia surveillance system project investigators. Am J Hematol. 1998;59(4):288–294.9840909
   PubMed Web of Science ®Google Scholar
• World Federation of Hemophilia. What is hemophilia? Availble from: https://www.wfh.org/en/page.aspx?pid=646. [Updated 5 2012]. Accessed 1015 2018.
   Google Scholar
• Rodriguez-Merchan EC. Prevention of the musculoskeletal complications of hemophilia. Adv Prev Med. 2012;2012:201271. doi:10.1155/2012/20127122778972
   PubMedGoogle Scholar
• Gater A, Thomson TA, Strandberg-Larsen M. Haemophilia B: impact on patients and economic burden of disease. Thromb Haemost. 2011;106(3):398–404. doi:10.1160/TH11-03-019321833450
   PubMed Web of Science ®Google Scholar
• O’Hara J, Walsh S, Camp C, et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes. 2018;16(1):84. doi:10.1186/s12955-018-0908-929720192
   PubMed Web of Science ®Google Scholar
• Miners AH, Sabin CA, Tolley KH, Jenkinson C, Kind P, Lee CA. Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia. 1999;5(6):378–385.10583523
   PubMed Web of Science ®Google Scholar
• Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis. 2012;7:24. doi:10.1186/1750-1172-7-4722551339
   PubMed Web of Science ®Google Scholar
• Naraine VS, Risebrough NA, Oh P, et al. Health-related quality-of-life treatments for severe haemophilia: utility measurements using the Standard Gamble technique. Haemophilia. 2002;8(2):112–120.11952846
   PubMed Web of Science ®Google Scholar
• O’Hara J, Hughes D, Camp C, Burke T, Carroll L, Diego DG. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017;12(1):106. doi:10.1186/s13023-017-0660-y28569181
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Position statement on use of the EQ-5D-5L valuation set. Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisal-guidance/eq5d5l_nice_position_statement.pdf. Published 2017 Accessed 115 2018.
   Google Scholar
• Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van Den Berg HM, Srivastava A. Definitions in hemophilia: communication from the SSC of the ISTH. J Thrombosis Haemostasis. 2014;12(11):1935–1939. doi:10.1111/jth.12672
   PubMed Web of Science ®Google Scholar
• EuroQol Group. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.10109801
   PubMed Web of Science ®Google Scholar
• Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. Bmj. 1998;316(7133):736–741. doi:10.1136/bmj.316.7133.7369529408
   PubMed Web of Science ®Google Scholar
• Dolan P. Aggregating health state valuations. J Health Serv Res Policy. 1997;2(3):160–165; discussion 166–167. doi:10.1177/135581969700200306
   Google Scholar
• Ware JE Jr., Kosinski M, Bjorner JB, Turner-Bowder DM, Gandek B, Maruish ME. User’s Manual for the SF-36v2^TM Health Survey (2nd Ed.). Lincoln, RI: QualityMetric Incorporated; 2007.
   Google Scholar
• Ware JE Jr., Sherbourne CD, The MOS. 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483.1593914
   PubMed Web of Science ®Google Scholar
• Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–292.11939242
   PubMed Web of Science ®Google Scholar
• Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 health survey. J Clin Epidemiol. 1998;51(11):1115–1128.9817129
   PubMed Web of Science ®Google Scholar
• Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 health survey in nine countries: results from the IQOLA project. International quality of life assessment. J Clin Epidemiol. 1998;51(11):1171–1178.9817135
   PubMed Web of Science ®Google Scholar
• Konig HH, Bernert S, Angermeyer MC, et al. Comparison of population health status in six european countries: results of a representative survey using the EQ-5D questionnaire. Med Care. 2009;47(2):255–261. doi:10.1097/MLR.0b013e318184759e19169128
   PubMed Web of Science ®Google Scholar
• Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. York, UK: Centre for Health Economics, University of York; 1999.
   Google Scholar
• Noone D, O’Mahony B, van Dijk JP, Prihodova L. A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18–35-year old men with severe haemophilia in six countries. Haemophilia. 2013;19(1):44–50. doi:10.1111/j.1365-2516.2012.02934.x22913831
   PubMed Web of Science ®Google Scholar
• van Den Berg B. SF-6D POPULATION NORMS. Health Econ. 2012;21(12):1508–1512. doi:10.1002/hec.182322250070
   PubMed Web of Science ®Google Scholar
• Hartl HK, Reitter S, Eidher U, Ramschak H, Ay C, Pabinger I. The impact of severe haemophilia on the social status and quality of life among Austrian haemophiliacs. Haemophilia. 2008;14(4):703–708. doi:10.1111/j.1365-2516.2008.01684.x18384355
   PubMed Web of Science ®Google Scholar
• Holstein K, von Mackensen S, Bokemeyer C, Langer F. The impact of social factors on outcomes in patients with bleeding disorders. Haemophilia. 2016;22(1):46–53. doi:10.1111/hae.1276026207763
   PubMed Web of Science ®Google Scholar
• Meunier S, Trossaert M, Berger C, et al. [French guidelines. Long-term prophylaxis for severe haemophilia A and B children to prevent haemophiliac arthropathy]. Archives De Pediatrie. 2009;16(12):1571–1578.19960603
   PubMed Web of Science ®Google Scholar
• Hoxer CS, Zak M, Benmedjahed K, Lambert J. Utility valuation of health states for haemophilia and related complications in Europe and in the United States. Haemophilia 2019;25(1):92–100.
   Google Scholar
• Carvalhosa AM, Henrard S, Lambert C, Hermans C. Physical and mental quality of life in adult patients with haemophilia in Belgium: the impact of financial issues. Haemophilia. 2014;20(4):479–485. doi:10.1111/hae.1234124354566
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Franchini M. Is haemophilia B less severe than haemophilia A? Haemophilia. 2013;19(4):499–502. doi:10.1111/hae.1213323517072
   PubMed Web of Science ®Google Scholar
• Nagel K, Walker I, Decker K, Chan AK, Pai MK. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients. Haemophilia. 2011;17(6):872–874. doi:10.1111/j.1365-2516.2011.02506.x21342368
   PubMed Web of Science ®Google Scholar
• Matcham F, Scott IC, Rayner L, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):123–130. doi:10.1016/j.semarthrit.2014.05.00124973898
   PubMed Web of Science ®Google Scholar
• Strand V, Sharp V, Koenig AS, et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis. 2012;71(7):1143–1150. doi:10.1136/annrheumdis-2011-20038722258482
   PubMed Web of Science ®Google Scholar
• Chen J, Wong CKH, McGhee SM, Pang PKP, Yu WC. A comparison between the EQ-5D and the SF-6D in patients with chronic obstructive pulmonary disease (COPD). PLoS One. 2014;9:11.
   Google Scholar
• van Stel HF, Buskens E. Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease. Health Qual Life Outcomes. 2006;4:20. doi:10.1186/1477-7525-4-2016563170
   PubMed Web of Science ®Google Scholar
• Pennington B, Hernandez-Alava M, Pudney S, Wailoo A. The impact of moving from EQ-5D-3L to −5L in NICE Technology Appraisals. PharmacoEconomics.
   Web of Science ®Google Scholar